Branded pharma with major oncology (Opdivo), hematology (Eliquis, Revlimid) and neuroscience (Cobenfy) franchises.
Branded pharma with major oncology (Opdivo), hematology (Eliquis, Revlimid) and neuroscience (Cobenfy) franchises.
Sells patented medicines through health systems and payers, with much of revenue from a handful of drugs, several of which lose patent protection this decade. Eliquis is shared with Pfizer. The 2019 Celgene purchase brought Revlimid, and Cobenfy came from the 2024 Karuna deal.
Moat: narrow (IP / patents, scale). Strong patent-protected franchises but facing near-term loss of exclusivity on key products.
Headquarters: New York, New York, United States · Founded: 1989 · Employees: 32,500
Size Bristol Myers Squibb (BMY) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $122B, the 102nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $59.56 on 18 Nov 2026.
Performance Over six months the shares gained 2.9%, against +12.0% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 4.2% over the last twelve months (peer median +6.1%); the operating margin is 32.9% (peer median 24.0%).
Valuation It trades at 9.2× forward earnings against a peer median of 17.5× (cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -16 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 17.1 points above its cost of capital (6.3% WACC).
Credit Bristol Myers Squibb has 34 bonds outstanding ($36.0B), rated A by the agencies and trading like A+ at a weighted spread of 76 bp.
Short interest Short interest is 2.3% of the free float (30 Oct 2026).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $50.0B | $48.2B | $48.3B | $45.0B | $46.2B |
| Revenue growth | — | 0% | +7% | -2% | — |
| Gross profit | $33.2B | $31.8B | $27.4B | $25.4B | $26.5B |
| EBITDA | $19.4B | $19.2B | $19.3B | $18.3B | $19.6B |
| Net income | $9.24B | $7.05B | -$8.95B | $8.03B | $6.33B |
| Free cash flow | $9.29B | $12.8B | $13.9B | $12.7B | $11.9B |
| Capital expenditure | $1.37B | $1.31B | $1.25B | $1.21B | $1.12B |
| Total debt | $44.8B | $47.1B | $51.2B | $41.5B | $40.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 9.2× | -13.1% |
| Merck & MRK | $340B | +23% | +5% | 18% | 16.4× | 8.3% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 18.1× | -0.1% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BMY | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.4% | +4.3% | 3rd lowest of 21 |
| 6-month return | +2.9% | +12.0% | 7th lowest of 21 |
| Distance from 52-week high | -13.2% | -7.4% | 8th lowest of 21 |
| Revenue growth (TTM) | +4.2% | +6.1% | 6th lowest of 21 |
| Operating margin | 32.9% | 24.0% | 5th highest of 21 |
| Forward P/E | 9.2× | 17.5× | cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -13.1% | 6.2% | least demanding of 20 |
| Growth delivered (Del g) | +2.5% | +9.3% | 4th lowest of 20 |
| Hurdle (Req g minus delivered) | -15.7 pp | -3.4 pp | 3rd least demanding of 20 |
| ROIC minus cost of capital | +17.1 pp | +4.8 pp | 6th highest of 21 |
| EV / EBITDA | 7.9× | 14.9× | 3rd cheapest of 19 |
| Net debt / EBITDA | 1.7× | 1.2× | 8th most indebted of 19 |
| Bond spread | 76 bp | 70 bp | 6th widest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb BMY | United States | $122B | +3% | +4% | 33% | 9.2× | -13.1% | +2.5% |
| Sanofi SAN.PA | France | $114B | +13% | +15% | 27% | 9.7× | -4.8% | +3.9% |
| Vertex Pharmaceuticals VRTX | United States | $136B | +25% | +11% | 35% | 28.5× | 6.2% | +14.2% |
| GSK GSK.L | United Kingdom | $97.9B | -3% | +4% | 25% | 10.4× | -0.1% | -0.9% |
| Regeneron Pharmaceuticals REGN | United States | $97.8B | +46% | +19% | 30% | 11.8× | -1.1% | +11.0% |
| Pfizer PFE | United States | $160B | +9% | +1% | 26% | 9.9× | -4.3% | +8.5% |
| Novo Nordisk A/S NOVO-B.CO | Denmark | $177B | -6% | +6% | 48% | 11.8× | -0.5% | +19.5% |
| Chugai Pharmaceutical 4519.T | Japan | $75.2B | -8% | +17% | 50% | 23.7× | 5.0% | +9.8% |
| Merck KGaA MRK.DE | Germany | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% | +3.8% |
| Takeda Pharmaceutical 4502.T | Japan | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% | +7.1% |
| WuXi AppTec 603259.SS | China | $64.2B | +40% | +32% | 43% | 17.0× | 7.2% | +22.3% |
| Bayer BAYN.DE | Germany | $60.3B | +48% | 0% | 13% | 12.3× | n/a | n/a |
| AstraZeneca AZN.L | United Kingdom | $278B | -2% | +5% | 23% | 17.6× | 14.4% | +15.7% |
| Novartis NOVN.SW | Switzerland | $285B | +11% | -4% | 30% | 17.5× | 1.6% | -0.2% |
| Galderma GALD.SW | Switzerland | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% | +6.4% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | India | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% | +11.7% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | China | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% | +2.7% |
| BeOne Medicines 688235.SS | China | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% | +79.3% |
| Merck & MRK | United States | $340B | +23% | +5% | 18% | 16.4× | 8.3% | +9.3% |
| Sandoz SDZ.SW | Switzerland | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% | +0.4% |
| Otsuka Hldgs 4578.T | Japan | $39.9B | +9% | +11% | 18% | 16.8× | 1.6% | +11.7% |
Bristol Myers Squibb has 34 bonds outstanding with $36.0B face value. The agencies rate it A; its bonds trade like A+. Weighted yield 5.72%, a spread of 76 bp over government bonds.